Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...